Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151953 | 0.86 | CA1 (0.67) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL23600 | 0.80 | CA1 (0.80) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL28993944 | 0.80 | CA1 (0.80) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL19846768 | 0.79 | CA1 (0.47) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL12142609 | 0.79 | CA1 (0.59) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL12565754 | 0.79 | MAPT (0.61) | MAPTSTSTSHRKMT2ARAB9A | |
| Methyl 4-Methoxybenzoate SCHEMBL231243 | 0.79 | CA1 (1.00) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL69218 | 0.79 | CA1 (0.75) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL16141147 | 0.78 | HPGD (0.66) | CA1CA2TSHRSMN1; SMN2 | |
| SCHEMBL11946638 | 0.78 | SMN1; SMN2 (0.54) | MAPTTSHRKMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230194165-A1 | RADIOFREQUENCY HEATING OF WOOD USING A THREE-ELECTRODE SYSTEM HAVING A WINGED CENTRAL ELECTRODE | RF KILN TECH LIMITED (CA) | 2023-06-22 | — | — | US | disclosed |
| US-11666637-B2 | Insulin-loaded metal-organic frameworks | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9931379-B2 | Oxyntomodulin analogs and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170196940-A1 | OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20130237411-A1 | Novel Strategies, Linkers and Coordination Polymers for High-Performance Sorbents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130131344-A1 | ORGANO-METALLIC FRAMEWORKS DERIVED FROM CARBENOPHILIC METALS AND METHODS OF MAKING SAME | BASF SE (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120259117-A1 | ORGANO-METALLIC FRAMEWORKS AND METHODS OF MAKING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037583-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | CA1 4864/4885CA2 4642/4885MAPT 4542/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CA1 4669/4885CA2 3833/4885MAPT 3800/4885 |
| US-11666637-B2 | Insulin-loaded metal-organic frameworks | IAPP, IGFBP4, IGFBP1 | CA1 1198/4885CA2 516/4885MAPT 2858/4885 |
| US-20130237411-A1 | Novel Strategies, Linkers and Coordination Polymers for High-Performance Sorbents | ILK, TIMCC, EPCAM | CA1 725/4885CA2 656/4885MAPT 637/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA1 4881/4885CA2 4788/4885MAPT 3230/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | CA1 4741/4885CA2 4368/4885MAPT 2199/4885 |
| US-20170196940-A1 | OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME | PTMS, OGFRL1, SHBG | CA1 1313/4885CA2 2917/4885MAPT 3705/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | CA1 1664/4885CA2 2888/4885MAPT 3282/4885 |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | CA1 192/4885CA2 1470/4885MAPT 151/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA1 4881/4885CA2 4783/4885MAPT 3250/4885 |
| US-20120259117-A1 | ORGANO-METALLIC FRAMEWORKS AND METHODS OF MAKING SAME | HNRNPF, EPCAM, YTHDF2 | CA1 760/4885CA2 831/4885MAPT 2130/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CA1 4881/4885CA2 4783/4885MAPT 3250/4885 |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | CA1 4467/4885CA2 2159/4885MAPT 3317/4885 |
| US-20130131344-A1 | ORGANO-METALLIC FRAMEWORKS DERIVED FROM CARBENOPHILIC METALS AND METHODS OF MAKING SAME | CA6, GZMB, PMS2 | CA1 209/4885CA2 68/4885MAPT 3648/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | CA1 1149/4885CA2 1841/4885MAPT 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.